Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections

References

• Dykhuizen RS, Trent RJ, Pacitti DP, et al. An analysis of 900 consecutive admissions to a regional infection unit. J Infect 1994;29:189-93
   PubMedGoogle Scholar
• Nathwani D, Moitra S, Dunbar J, et al. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract 1998;52:456-60
   PubMedGoogle Scholar
• Tice AD, Poretz D, Cook F, et al. Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself. Clin Infect Dis 1998;27:1415-21
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Soft tissue infections among injection drug users—San Francisco, California, 1996–2000. MMWR 2001;50:381-4
   PubMedGoogle Scholar
• LaPensee K, Fan W. Economic burden of hospitalization with antibiotic treatment for ABSSSI in the US: an analysis of the Premier Hospital Database. Poster code: PIN222012. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting. Washington, DC; 2012
   Google Scholar
• Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311-20
   PubMed Web of Science ®Google Scholar
• Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:283-95
   PubMedGoogle Scholar
• Swartz MN. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A 1994;91:2420-7
   PubMed Web of Science ®Google Scholar
• Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-11
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-74
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9
   PubMed Web of Science ®Google Scholar
• Lodise TP, Jr McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007;27:1001-12
   PubMed Web of Science ®Google Scholar
• Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005;26:175-83
   PubMed Web of Science ®Google Scholar
• Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007;28:273-9
   PubMed Web of Science ®Google Scholar
• Chapman AL, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012;67:1053-62
   PubMed Web of Science ®Google Scholar
• Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38:1651-72
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Zargarzadeh A, Hsu DI, et al. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011;14:631-9
   PubMed Web of Science ®Google Scholar
• De Cock E, Sorensen S, Levrat F, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect 2009;39:330-40
   PubMed Web of Science ®Google Scholar
• Shah NP, Reddy P, Paladino JA, et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin 2004;20:779-90
   PubMed Web of Science ®Google Scholar
• Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res 2013;5:447-57
   PubMedGoogle Scholar
• Fan W, Mao J, Iorga S, et al. Care pathway and health care cost for acute bacterial skin and skin structure infection subjects with antibiotic treatment in the US: analysis of a real world database. Poster code: PRM742013. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting. New Orleans, LA; 2013
   Google Scholar
• White B, Seaton RA. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 2011;4:115-27
   PubMedGoogle Scholar
• Medicare Standard Analytical Files – 5% Sample. Baltimore, MD: Centers for Medicare and Medicaid Services, 2009–2010. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/IdentifiableDataFiles/StandardAnalyticalFiles.html. Accessed, 2013
   Google Scholar
• LaPensee K, Lodise TP, Fan W, et al. Comparison of efficacy and adverse events between oritavancin versus vancomycin among patients treated in the ambulatory setting in SOLO I. Poster Code: 2303. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver, CO; 2013
   Google Scholar
• Berger A, Oster G, Edelsberg J, et al. Failure of initial antibiotic therapy in complicated skin and skin structure infections (cSSSI) in US hospitals, 2000–2009. Infectious Diseases Society of America 48th Annual Meeting. Vancouver, Canada; 2010
   Google Scholar
• Fan W, LaPensee K, Mao J, et al. Direct medical costs and healthcare resource utilization associated with selected antibiotic treatment pathways in acute bacterial skin and skin structure infections in US. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress. Dublin, Ireland; 2013
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55 (Erratum in: Clin Infect Dis 2011;53:319)
   PubMed Web of Science ®Google Scholar
• Ball AT, Xu Y, Sanchez RJ, et al. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther 2010;32:2246-55
   PubMedGoogle Scholar
• Klevens RM, Edwards JR, Richards J, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122:160-6
   PubMed Web of Science ®Google Scholar
• Roberts RR, Scott RD 2nd, Hota B, et al. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010;48:1026-35
   PubMedGoogle Scholar
• Physicians’ Desk Reference® PDR-3D: Digital Drug Database. Montvale, NJ: PDR Network LLC, 2013. http://www.pdr3d.com/. Accessed 2013
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Clinical Laboratory Fee Schedule. 2012. Baltimore, MD: Centers for Medicare & Medicaid Services, 2012. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed 2012
   Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Red Book® Online. Elk Grove IL: American Academy of Pediatrics, 2012. Available at: http://aapredbook.aappublications.org/ [Last accessed May 30, 2014]
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Physician Fee Schedule National Payment Amount File. Baltimore, MD: Centers for Medicare & Medicaid Services, 2012. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-National-Payment-Amount-File.html. Accessed 2012
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Hospital Outpatient Prospective Payment System. Baltimore, MD: Centers for Medicare & Medicaid Services, 2013. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html. Accessed 2013
   Google Scholar